Last reviewed · How we verify

Ultra-Long GnRH Agonists + Letrozole

University of Palermo · FDA-approved active Small molecule

Ultra-long GnRH agonists suppress gonadal hormone production while letrozole blocks aromatase to inhibit estrogen synthesis, creating a dual hormonal suppression strategy.

Ultra-long GnRH agonists suppress gonadal hormone production while letrozole blocks aromatase to inhibit estrogen synthesis, creating a dual hormonal suppression strategy. Used for Hormone receptor-positive breast cancer in premenopausal women, Endometriosis.

At a glance

Generic nameUltra-Long GnRH Agonists + Letrozole
SponsorUniversity of Palermo
Drug classGnRH agonist + aromatase inhibitor combination
TargetGnRH receptor; aromatase (CYP19A1)
ModalitySmall molecule
Therapeutic areaOncology; Gynecology
PhaseFDA-approved

Mechanism of action

GnRH agonists desensitize the pituitary gland to suppress luteinizing hormone and follicle-stimulating hormone, thereby reducing ovarian estrogen production. Letrozole, an aromatase inhibitor, further blocks peripheral conversion of androgens to estrogen. This combination achieves profound estrogen deprivation, used primarily in hormone-sensitive breast cancer and endometriosis management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: